Molbio Diagnostics IPO Allotment Expected Today with a 20% GMP — Here’s How to Check Your Status!

The much-anticipated IPO of Molbio Diagnostics is nearing its final stages, with the basis of allotment set to be finalized on Thursday. Investors who applied for a portion of the Rs 939.70-crore issue can now verify their allotment status online. The IPO was open from August 10 to August 12 and received an impressive subscription rate of 70.26 times overall, with qualified institutional buyers (QIBs) leading the charge at a staggering 186.39 times. The price band for the IPO was fixed at Rs 768–Rs 807 per share, and the listing is expected to take place on August 17 on both the BSE and NSE. The issue consists of a fresh issue of 25 lakh shares worth Rs 200 crore and an offer for sale (OFS) of 92 lakh shares valued at Rs 739.70 crore.

The grey market sentiment surrounding the Molbio Diagnostics IPO remains strong, with the latest grey market premium (GMP) around Rs 154 per share, translating to an approximate 20% premium compared to the upper price band of Rs 807. Should this sentiment hold, the stock could debut at around Rs 961 per share, indicating a healthy potential gain for investors. However, it’s important to note that GMP is an unofficial market indicator and is subject to fluctuations as the listing date approaches. Investors should remain cautious, as while the current sentiment points towards positive returns, market conditions can change rapidly.

For Indian investors, the Molbio Diagnostics IPO represents an opportunity to invest in a company that is not only financially robust—with a reported 42% year-on-year increase in total income—but also in a sector that is gaining traction due to the growing demand for rapid diagnostic solutions. The funds raised through the IPO will primarily be directed towards enhancing its research and development capabilities and expanding infrastructure, key elements in maintaining competitiveness in the fast-evolving healthcare landscape. As the company’s offerings span critical areas like tuberculosis, COVID-19, and HIV diagnostics, its capital market entry comes at a time when healthcare continues to be a high priority globally. This presents both growth potential and a pivotal investment opportunity for stakeholders in the Indian market.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)